Product Code: GVR-4-68038-580-9
Biological Safety Cabinets Market Growth & Trends:
The global biological safety cabinet market size is expected to reach USD 352.41 million by 2030, registering a CAGR of 7.62%, according to a new report by Grand View Research, Inc. Technological advancements due to a rise in laboratory procedures performed that play a crucial role in the safety of personnel, product, and environment, have propelled the market growth. The introduction of smart biosafety cabinets, such as PureLogic+ manufactured by Labconco Inc., with new features and adjustable accessories is playing a crucial role in the growth of the market.
To improve the safety, efficacy, and maintenance, NCBI launched a biological safety cabinet certification program in 2016, which certifies the design, construction, performance, and field parameters of the cabinets. There are various initiatives like the biosafety management programs taken up by the government and private companies that include complete investigation of the cabinets.
Factors like the favorable regulations, increasing prevalence of communicable diseases and rising number of pharmaceutical companies and their R&D activities are anticipated to boost the market growth. However, high product costs and introduction of alternative containment cabinets like the compounding isolators are likely to restrain the market growth.
Biological Safety Cabinets Market Report Highlights:
- Class II type emerged as the largest product segment in 2023 owing to great efficiency and result delivery of these products
- The type A of Class II segment is projected to register the highest CAGR over the forecast period as they offer advantages, such as improved safety
- Pharmaceuticals and biopharmaceutical companies had the highest market share due to focus on R&D and innovation by these companies
- For instance, in 2018, NuAire launched LabGard ES NU 540, a series of advanced type II biological safety cabinets featuring AeroMax control system and HEPEX zero leak airflow system with dynamic air barrier that allows the technicians to work with precision and efficiency without the risk of contamination
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. End Use
- 1.2.3. Regional scope
- 1.2.4. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. End use outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Biological Safety Cabinets Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. The increasing need to safeguard product, agent, personnel, and the environment from biohazard exposure and cross-contamination during procedures
- 3.2.1.2. Increasing R&D activities
- 3.2.1.3. Rapid growth in the number of biologics
- 3.2.2. Market restraint analysis
- 3.2.2.1. High cost of biological safety cabinets
- 3.3. Biological Safety Cabinets Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
Chapter 4. Biological Safety Cabinets Market: Product Estimates & Trend Analysis
- 4.1. Product Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. Global Biological Safety Cabinets Market by Product Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. Class I
- 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.2. Class II
- 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.2.2. Class II Type A
- 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.2.3. Class II Type B
- 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.3. Class III
- 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Biological Safety Cabinets Market: End Use Estimates & Trend Analysis
- 5.1. End Use Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. Global Biological Safety Cabinets Market by End Use Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. Pharmaceutical & biopharmaceutical companies
- 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.2. Diagnostics & testing laboratories
- 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.3. Academic & research organizations
- 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Biological Safety Cabinets Market: Regional Estimates & Trend Analysis
- 6.1. Regional Market Share Analysis, 2023 & 2030
- 6.2. Regional Market Dashboard
- 6.3. Global Regional Market Snapshot
- 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 6.5. North America
- 6.5.1. U.S.
- 6.5.1.1. Key country dynamics
- 6.5.1.2. Regulatory framework/ reimbursement structure
- 6.5.1.3. Competitive scenario
- 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.2. Canada
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Regulatory framework/ reimbursement structure
- 6.5.2.3. Competitive scenario
- 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Europe
- 6.6.1. UK
- 6.6.1.1. Key country dynamics
- 6.6.1.2. Regulatory framework/ reimbursement structure
- 6.6.1.3. Competitive scenario
- 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.2. Germany
- 6.6.2.1. Key country dynamics
- 6.6.2.2. Regulatory framework/ reimbursement structure
- 6.6.2.3. Competitive scenario
- 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.3. France
- 6.6.3.1. Key country dynamics
- 6.6.3.2. Regulatory framework/ reimbursement structure
- 6.6.3.3. Competitive scenario
- 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.4. Italy
- 6.6.4.1. Key country dynamics
- 6.6.4.2. Regulatory framework/ reimbursement structure
- 6.6.4.3. Competitive scenario
- 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.5. Spain
- 6.6.5.1. Key country dynamics
- 6.6.5.2. Regulatory framework/ reimbursement structure
- 6.6.5.3. Competitive scenario
- 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.6. Norway
- 6.6.6.1. Key country dynamics
- 6.6.6.2. Regulatory framework/ reimbursement structure
- 6.6.6.3. Competitive scenario
- 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.7. Sweden
- 6.6.7.1. Key country dynamics
- 6.6.7.2. Regulatory framework/ reimbursement structure
- 6.6.7.3. Competitive scenario
- 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.8. Denmark
- 6.6.8.1. Key country dynamics
- 6.6.8.2. Regulatory framework/ reimbursement structure
- 6.6.8.3. Competitive scenario
- 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7. Asia Pacific
- 6.7.1. Japan
- 6.7.1.1. Key country dynamics
- 6.7.1.2. Regulatory framework/ reimbursement structure
- 6.7.1.3. Competitive scenario
- 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.2. China
- 6.7.2.1. Key country dynamics
- 6.7.2.2. Regulatory framework/ reimbursement structure
- 6.7.2.3. Competitive scenario
- 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.3. India
- 6.7.3.1. Key country dynamics
- 6.7.3.2. Regulatory framework/ reimbursement structure
- 6.7.3.3. Competitive scenario
- 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.4. Australia
- 6.7.4.1. Key country dynamics
- 6.7.4.2. Regulatory framework/ reimbursement structure
- 6.7.4.3. Competitive scenario
- 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.5. South Korea
- 6.7.5.1. Key country dynamics
- 6.7.5.2. Regulatory framework/ reimbursement structure
- 6.7.5.3. Competitive scenario
- 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.6. Thailand
- 6.7.6.1. Key country dynamics
- 6.7.6.2. Regulatory framework/ reimbursement structure
- 6.7.6.3. Competitive scenario
- 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 6.8. Latin America
- 6.8.1. Brazil
- 6.8.1.1. Key country dynamics
- 6.8.1.2. Regulatory framework/ reimbursement structure
- 6.8.1.3. Competitive scenario
- 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 6.8.2. Mexico
- 6.8.2.1. Key country dynamics
- 6.8.2.2. Regulatory framework/ reimbursement structure
- 6.8.2.3. Competitive scenario
- 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 6.8.3. Argentina
- 6.8.3.1. Key country dynamics
- 6.8.3.2. Regulatory framework/ reimbursement structure
- 6.8.3.3. Competitive scenario
- 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 6.9. MEA
- 6.9.1. South Africa
- 6.9.1.1. Key country dynamics
- 6.9.1.2. Regulatory framework/ reimbursement structure
- 6.9.1.3. Competitive scenario
- 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 6.9.2. Saudi Arabia
- 6.9.2.1. Key country dynamics
- 6.9.2.2. Regulatory framework/ reimbursement structure
- 6.9.2.3. Competitive scenario
- 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.9.3. UAE
- 6.9.3.1. Key country dynamics
- 6.9.3.2. Regulatory framework/ reimbursement structure
- 6.9.3.3. Competitive scenario
- 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 6.9.4. Kuwait
- 6.9.4.1. Key country dynamics
- 6.9.4.2. Regulatory framework/ reimbursement structure
- 6.9.4.3. Competitive scenario
- 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company/Competition Categorization
- 7.3. Vendor Landscape
- 7.3.1. List of key distributors and channel partners
- 7.3.2. Key customers
- 7.3.3. Key company market share analysis, 2023
- 7.3.4. Thermo Fisher Scientific, Inc.
- 7.3.4.1. Company overview
- 7.3.4.2. Financial performance
- 7.3.4.3. Product benchmarking
- 7.3.4.4. Strategic initiatives
- 7.3.5. Labconco Corp.
- 7.3.5.1. Company overview
- 7.3.5.2. Financial performance
- 7.3.5.3. Product benchmarking
- 7.3.5.4. Strategic initiatives
- 7.3.6. NuAire, Inc.
- 7.3.6.1. Company overview
- 7.3.6.2. Financial performance
- 7.3.6.3. Product benchmarking
- 7.3.6.4. Strategic initiatives
- 7.3.7. The Baker Company, Inc.
- 7.3.7.1. Company overview
- 7.3.7.2. Financial performance
- 7.3.7.3. Product benchmarking
- 7.3.7.4. Strategic initiatives
- 7.3.8. AZBIL TELSTAR, S.L.U.
- 7.3.8.1. Company overview
- 7.3.8.2. Financial performance
- 7.3.8.3. Product benchmarking
- 7.3.8.4. Strategic initiatives
- 7.3.9. Jinan Biobase Biotech Co. Ltd.
- 7.3.9.1. Company overview
- 7.3.9.2. Financial performance
- 7.3.9.3. Product benchmarking
- 7.3.9.4. Strategic initiatives
- 7.3.10. Germfree Laboratories, Inc.
- 7.3.10.1. Company overview
- 7.3.10.2. Financial performance
- 7.3.10.3. Product benchmarking
- 7.3.10.4. Strategic initiatives
- 7.3.11. Air Science USA LLC
- 7.3.11.1. Company overview
- 7.3.11.2. Financial performance
- 7.3.11.3. Product benchmarking
- 7.3.11.4. Strategic initiatives
- 7.3.12. Haier Biomedical (Qingdao Biomedical Co., Ltd.)
- 7.3.12.1. Company overview
- 7.3.12.2. Financial performance
- 7.3.12.3. Product benchmarking
- 7.3.12.4. Strategic initiatives
- 7.3.13. Cruma S.A.
- 7.3.13.1. Company overview
- 7.3.13.2. Financial performance
- 7.3.13.3. Product benchmarking
- 7.3.13.4. Strategic initiatives